Gå direkt till huvudinnehållet

Ovarialcancer

Senast uppdaterad: Senast reviderad:
Sakkunnig:

Definition:
Ovarialcancer omfattar flera tumörtyper och indelas grovt i epiteliala tumörer och icke epiteliala tumörer.
Förekomst:
13 av 100 000 kvinnor insjuknar årligen i ovarialcancer i Sverige. Kvinnor i alla åldrar kan drabbas med högst incidens i 70-årsåldern
Symtom:
I tidiga stadier ger sjukdomen få symtom. Lindriga och ospecifika bukbesvär kan förekomma. Sådana symtom som uppsvälld och utspänd buk, underlivsblödning, nedsatt aptit, frekvent blåstömning, buksmärtor och rektal blödning är associerad med förekomst av ovarialcancer, men det prediktiva värdet för enskilda symtom är mycket låg.
Kliniska fynd:
Palpabel tumör i adnexa. Hård, oregelbunden, fixerad resistens tyder på malignitet. Välgrundad misstanke enligt standardiserat vårdförlopp, se kortversion för primärvården (RCC). 
Diagnostik:
Diagnosen ställs vid gynekologisk undersökning med ultraljud tillsammans med blodprover och bildundersökningar, eventuellt biopsi.
Behandling:
Kirurgi är huvudbehandlingen. Cytostatika kan vara aktuellt.
  1. Nationellt vårdprogram epitelial äggstockscancer, RCC 2022 www.cancercentrum.se  
  2. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016 Jun 1;93(11):937-944. PMID: 27281838 PubMed  
  3. Javadi S, Ganeshan DM, Qayyum A et al. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. AJR Am J Roentgenol. 2016 Jun;206(6):1351-60. PMID: 27042752 PubMed  
  4. Nationellt vårdprogram Icke-epiteliala äggstockstumörer Nationellt vårdprogram, RCC 2018 www.cancercentrum.se  
  5. Bertelsen K, Knudsen JB. Ovariecancer. Ugeskr Læger 2002; 164: nr. 23.
  6. Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol 2018. PMID: 29346467 PubMed  
  7. Barnett GL, Friedrich CA. Recent developments in ovarian cancer genetics. Curr Opin Obstet Gynecol 2004; 16: 79-85. PubMed  
  8. Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 2010;85(12):1111–1120. PMID: 21123638 PubMed  
  9. Uancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis and mortality. Cancer 1993; 71: 517-23. PubMed  
  10. King MC, Mrks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutation in BRCA1 and BRCA2 . Science 2003; 302(5645)643-6
  11. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3–23.
  12. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–1333.
  13. Adami H-O, Hseih C-C, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344: 1250-4. PubMed  
  14. Jordan SJ1, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103: 1122-9. pmid:17005245 PubMed  
  15. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1·1 million Norwegian women. J Natl Cancer Inst 2003; 95: 1244-48. PubMed  
  16. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø. Hormon therapy and ovarian cancer. JAMA 2009; 302: 298-305. Journal of the American Medical Association  
  17. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015. pmid: 25684585 PubMed  
  18. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–4198. PMID: 24145348 PubMed  
  19. Iversen L, Fielding S, Lidegaard Ø, et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study BMJ 2018; 362 :k3609. PMID: 30257920 PubMed  
  20. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer: a Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol 2004; 33: 596-602. PubMed  
  21. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103: 785-94. PubMed  
  22. Jensen A, Sharif H, Frederiksen K, Kjær SK. Use of fertility drug and risk of ovarian cancer: Danish population based cohort study. BMJ 2009; 338: b249. BMJ (DOI)  
  23. Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol 2007; 109: 1053-61. PubMed  
  24. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109: 221-7. PubMed  
  25. Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009; 339: b2998. BMJ (DOI)  
  26. Barney SP, Muller CY, Bradshaw KD. Pelvic masses. Med Clin North Am 2008; 92: 1143-61. PubMed  
  27. Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol 2007; 8: 1054-5. PubMed  
  28. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529.
  29. Liu JH, Zanotti KM. Management of the adnexal mass. Obstet Gynecol. 2011;117(6):1413–1428. PMID: 21606754 PubMed  
  30. Ameye L, et al. Clinically oriented three-step strategy for assessment of adnexal pathology. Ultrasound Obstet Gynecol. 2012;40(5):582–591.
  31. Timmerman D, Ameye L, Fischerova D et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. Bmj. 2010;341:c6839. PMID: 21156740 PubMed  
  32. Tingulstad S., Hagen B., Skjeldestad FE. . The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals.. Obstet Gynecol 1999; 93(3): 448-52. pmid:10074998 PubMed  
  33. Primärvårdsversion av standardiserat vårdförlopp för cancer äggstockscancer, RCC (hämtad 2019-09-18) www.cancercentrum.se  
  34. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; 371: 303-14. PubMed  
  35. Kasprzak L, Foulkes WD, Shelling AN. Hereditary ovarian carcinoma. BMJ 1999;318:786-9. British Medical Journal  
  36. Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician 2009; 80: 609-16. American Family Physician  
  37. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31: 539-57. PubMed  
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet

Tidigare sakkunniga

  • Barbro Larson, docent och specialist i gynekologi och obstetrik, Stockholm
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL